Eli Lilly is considering testing its blockbuster weight-loss drugs in people who are not overweight but are at risk of weight gain, in an early sign that the drugmaker may look to broaden the rollout of the medications beyond obese patients.

In a groundbreaking move, Eli Lilly (NYSE:LLY) is set to test its weight-loss medications on individuals who are not overweight but are at risk of gaining weight. What Happened: Dave Ricks, CEO of Eli Lilly,

But Lilly isn't alone in the market, and in the coming years, this space could become more crowded. Today, Lilly competes with Novo Nordisk, and in the future, companies like biotech giant Amgen and smaller biotech Viking Therapeutics to big pharma company Pfizer could enter the market with rival products.

Eli Lilly explores expanding its weight-loss drugs, Mounjaro and Zepbound, to individuals with a BMI below 27 to prevent health risks. CEO Dave Ricks emphasizes responsible use amid supply concerns.